Global Alzheimer's Disease Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 224 pages | ID: G4A70279185EN
Precision Business Insights (PBI)

Abstracts

Global Alzheimer's Disease Treatment Market:

Global alzheimer's disease treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for alzheimer's disease treatment is projected to reach US$ XX Mn by 2023.

Alzheimer's disease is a neurodegenerative disorder that attacks the brain's nerve cells, or neurons, leading to cell death and degeneration. The most common symptoms of Alzheimer's disease are the memory loss, incognition, disorientation, behavioural changes, personality changes, and trouble in speaking and writing. The Alzheimer's disease (AD) mainly occurs in the adults with aging mid-sixties, which leads to 60% to 70% of cases of dementia. The major causes of Alzheimer's disease are genetic disorders and the disease process associated with plaques and tangles in the brain. The diagnostic test for Alzheimer's disease includes cognitive testing with medical imaging and blood tests. Alzheimer’s disease risks can be overcome by mental and physical exercise and avoiding obesity.

The global Alzheimer’s disease treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Alzheimer’s disease. According to World Health Organisation, escalation of the geriatric population leads to increase in Alzheimer's disease cases, which in turn affect the Alzheimer's disease treatment market positively over the forecast period. Apart from this, increase in healthcare spending and R&D investments in the global Alzheimer’s research, expiration of patents, and entry of new generics into the market expected to fuel the growth of Alzheimer’s disease treatment market. Similarly, the discovery of new disease modifying drugs, and presence of vast last-stage pipeline drugs expected to boost the growth of Alzheimer’s disease treatment market over the forecast period. However, the limited number of treatment options for Alzheimer’s disease in the market, challenges in precise diagnosis and even detection of Alzheimer's disease, and lack of funding from government in developing economies for research might hamper the growth of global Alzheimer's disease treatment market over the forecast period. Moreover, the high degree of research failure and uncertainty within the research and development of Alzheimer's disease treatment drugs might hinder the growth of Alzheimer's disease treatment market.

Alzheimer's disease treatment market has been segmented on the basis of drug type, route of administration, and end user

Based on the drug type, Alzheimer's disease treatment market has been segmented into the following:

• Cholinesterase inhibitors
• NMDA receptor antagonists
• Others

Based on the route of administration, Alzheimer's disease treatment market has been segmented into the following:

• Oral
• Implants
• Others

Based on the distribution channel, Alzheimer's disease treatment market has been segmented into the following:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The Alzheimer’s disease treatment market is in the growing stage with several international players operating in the Alzheimer’s disease treatment market. According to Centres for Disease Control and Prevention (CDC) the global prevalence of Alzheimer’s disease will triple among elderly patients, and the prevalence increases to 13.8 million by 2050. Several drug molecules lost patents and few more expected lose patents in near future, which is expected to crate market opportunity for generic players. Majority of drugs in pipeline failed in the late stage of clinical trials, for instance, Eli Lilly's solanezumab and Pfizer/Johnson & Johnson’s bapineuzumab have failed to prove the disease-slowing effects in the late-stage of clinical trials. Moreover, In 2014, FDA has approved cholinesterase inhibitors (Exelon, Aricept, and Razadyne) and memantine for the treatment of cognitive symptoms in Alzheimer disease. The other medication is Namzaric (combination of donepezil with memantine) manufactured by Allergan for the treatment of Alzheimer’s disease. Researchers are looking for new ways to treat Alzheimer's disease to address the Alzheimer's disease market needs. Currently available drugs help mask the symptoms of Alzheimer's disease but they do not stop its progression. There are several promising drugs in developmental and testing stage for Alzheimer's disease, but researchers need more funding of research to ensure that fresh ideas continue to fill the pipeline.

Geographically, the Alzheimer’s disease treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. According to the United Nations Population Fund, the people aged over 60 make up for 12.3% of the world’s population, which is estimated to exceed to almost 22% by 2050, with the increase in geriatric population the market for Alzheimer’s drugs expected to bolster during the forecast period 2017 to 2023. North America contributes the maximum demand for Alzheimer’s drugs. According to the American Alzheimer’s Association, almost 5 Mn adults are suffering from Alzheimer’s disease and due to the increasing aging populations, it may expect to grow in future. Similarly, increasing coverage of Alzheimer's disease by Medicare, an insurance program encourages more Alzheimer's patients to seek medical treatment, expected driving market growth. According to Alzheimer’s Association UK, there are 850,000 people with dementia in the UK in 2015 which is expected to increase to approximately 1 Mn during forecasting period which expected to contribute significantly to the overall growth of the European Alzheimer’s disease treatment market.

Some of the players in global Alzheimer's disease treatment market are F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Eisai Pharmaceuticals Co. Ltd. (Japan), H. Lundbeck A/S (Denmark), Johnson & Johnson Services Inc., (U.S.), AstraZeneca (U.K.), Pfizer Inc. (U.S.), Forest Laboratories (U.S.), and Eli Lilly and Company (U.S.) to name a few.

In January 2015, Johnson & Johnson partnered with Swiss biopharma AC Immune to develop a therapeutic vaccine for the development of anti-tau Alzheimer’s vaccine

In September 2014, Eli Lilly and AstraZeneca came into an alliance to co-develop the partial treatment for Alzheimer's disease

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET INTRODUCTION

2.1. Global Alzheimer’s Disease Treatment Market– Taxonomy
2.2. Global Alzheimer’s Disease Treatment Market–Definitions
  2.2.1. Drug Type
  2.2.2. Distribution Channel

3. GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Alzheimer’s Disease Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Alzheimer’s Disease Treatment Market– Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan

4. GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Cholinesterase Inhibitors
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. NMDA Receptor Antagonists
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Others
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis

6. GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Oral
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Implants
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Others
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Alzheimer’s Disease Treatment Market- Opportunity Analysis Index - By Drug Type, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA ALZHEIMER’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Cholinesterase Inhibitors
    9.1.1.2. NMDA Receptor Antagonists
    9.1.1.3. Others
  9.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Oral
    9.1.2.2. Implants
    9.1.2.3. Others
  9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospital Pharmacies
    9.1.3.2. Retail Pharmacies
    9.1.3.3. Online Pharmacies
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Alzheimer’s Disease Treatment Market- Opportunity Analysis Index - By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  9.1.6. North America Alzheimer’s Disease Treatment Market Dynamics – Trends

10. EUROPE ALZHEIMER’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Cholinesterase Inhibitors
    10.1.1.2. NMDA Receptor Antagonists
    10.1.1.3. Others
  10.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Oral
    10.1.2.2. Implants
    10.1.2.3. Others
  10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospital Pharmacies
    10.1.3.2. Retail Pharmacies
    10.1.3.3. Online Pharmacies
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Alzheimer’s Disease Treatment Market- Opportunity Analysis Index - By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  10.1.6. Europe Alzheimer’s Disease Treatment Market Dynamics – Trends

11. ASIA-PACIFIC ALZHEIMER’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Cholinesterase Inhibitors
    11.1.1.2. NMDA Receptor Antagonists
    11.1.1.3. Others
  11.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Oral
    11.1.2.2. Implants
    11.1.2.3. Others
  11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospital Pharmacies
    11.1.3.2. Retail Pharmacies
    11.1.3.3. Online Pharmacies
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Alzheimer’s Disease Treatment Market- Opportunity Analysis Index - By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  11.1.6. Asia-Pacific Alzheimer’s Disease Treatment Market Dynamics – Trends

12. LATIN AMERICA ALZHEIMER’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Cholinesterase Inhibitors
    12.1.1.2. NMDA Receptor Antagonists
    12.1.1.3. Others
  12.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Oral
    12.1.2.2. Implants
    12.1.2.3. Others
  12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospital Pharmacies
    12.1.3.2. Retail Pharmacies
    12.1.3.3. Online Pharmacies
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Alzheimer’s Disease Treatment Market- Opportunity Analysis Index - By Drug Type, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  12.1.6. Latin America Alzheimer’s Disease Treatment Market Dynamics – Trends

13. MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Cholinesterase Inhibitors
    13.1.1.2. NMDA Receptor Antagonists
    13.1.1.3. Others
  13.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Oral
    13.1.2.2. Implants
    13.1.2.3. Others
  13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospital Pharmacies
    13.1.3.2. Retail Pharmacies
    13.1.3.3. Online Pharmacies
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Alzheimer’s Disease Treatment Market- Opportunity Analysis Index - By Drug Type, By Surgery, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  13.1.6. MEA Alzheimer’s Disease Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. F. Hoffmann-La Roche Ltd (Switzerland)
  14.2.2. Novartis AG (Switzerland)
  14.2.3. Eisai Pharmaceuticals Co. Ltd. (Japan)
  14.2.4. H. Lundbeck A/S (Denmark)
  14.2.5. Johnson & Johnson Services Inc., (U.S.)
  14.2.6. AstraZeneca (U.K.)
  14.2.7. Pfizer Inc. (U.S.)
  14.2.8. Forest Laboratories (U.S.)
  14.2.9. Eli Lilly and Company (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS